Skip to content
HowShorted

Editas Medicine, Inc. short interest in 2023

In 2023, Editas Medicine, Inc.'s disclosed short interest ran from 32.19% of shares outstanding on 13 Jan 2023 to 15.66% on 29 Dec 2023, a change of -16.53 percentage points. The year's high was 32.19% on 13 Jan 2023 and its low 15.66% on 29 Dec 2023, averaging 24.14% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.97 days on 31 Aug 2023. Full history: Editas Medicine, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Editas Medicine, Inc. in 2023

2023 in figures

Start of year
32.19% (13 Jan 2023)
End of year
15.66% (29 Dec 2023)
Change
-16.53 pp
High
32.19% (13 Jan 2023)
Low
15.66% (29 Dec 2023)
Average
24.14%
Highest days to cover
13.97 (31 Aug 2023)
SEC filings marked
8

Every report in 2023

Editas Medicine, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202332.19%10.58
31 Jan 202330.45%11.12
15 Feb 202328.60%10.93
28 Feb 202327.86%11.6910-K filed, results (8-K)
15 Mar 202330.01%13.55
31 Mar 202328.58%12.66
14 Apr 202329.01%8.77
28 Apr 202327.33%11.02
15 May 202329.31%8.6210-Q filed, results (8-K)
31 May 202329.71%12.96
15 Jun 202329.91%7.12
30 Jun 202328.17%6.39
14 Jul 202322.42%10.56
31 Jul 202318.92%11.76
15 Aug 202317.65%9.2910-Q filed, results (8-K)
31 Aug 202317.77%13.97
15 Sep 202318.60%11.45
29 Sep 202319.56%7.81
13 Oct 202320.12%11.20
31 Oct 202320.53%12.11
15 Nov 202319.43%7.8010-Q filed, results (8-K)
30 Nov 202319.33%8.52
15 Dec 202318.33%5.89
29 Dec 202315.66%7.01

See also: Editas Medicine, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.